quantbrah

Trading the situation. AI turns X posts into trackable portfolios. Not financial advice.

Long peptide-compounding platforms into the July 23 FDA catalyst, hedged against branded GLP-1 incumbents

The post is a direct financial thesis on the obesity/peptide ecosystem. The clearest investable angle is to go long the most direct beneficiaries of wider peptide compounding and retail distribution—especially HIMS and LFMD—while shorting branded GLP-1 incumbents NVO and LLY that could face pricing pressure if compounding expands. VKTX fits as the high-volatility upside call option on a reshuffled obesity market. This preserves the source post’s explicit long/short basket rather than diluting it with broader healthcare exposure.

ALL TIME RETURN +4.07%
S&P 500 +5.90%
VS S&P 500 -1.82%
Return +5.35%
S&P 500 -0.37%
VS S&P 500 +5.73%
Best performer VKTX +32.57%
Portfolio S&P 500 AS OF JUL 14, 8:40 PM
  • HIMS Long
    Performance +21.89%
    Current weight 36.22%

    Description Named by the post as the most direct play on peptide compounding expansion, with scale, subscribers, and infrastructure positioned to respond quickly if the FDA framework turns favorable.

  • LFMD Long
    Performance +10.39%
    Current weight 18.74%

    Description Presented as a cheaper, higher-beta HIMS analog with its own pharmacy and strong retention; fits the post’s view that it should rerate if the peptide tide rises.

  • LLY Short
    Performance -24.51%
    Current weight 15.86%

    Description Included exactly as the post’s other short-side incumbent. Even with a promising oral pipeline, the source thesis says expanded compounding and market reshuffling create a near-term hedge target.

  • NVO Short
    Performance -21.19%
    Current weight 15.43%

    Description The post explicitly frames Novo as a loser if compounding broadens, since cheaper alternatives could pressure branded GLP-1 economics and pricing power.

  • VKTX Long
    Performance +7.92%
    Current weight 13.74%

    Description Matches the post’s explicit 'lotto ticket' framing: a speculative small-cap obesity drug developer that could gain sharply if it emerges as a credible third player in GLP-1s.

Created
Last checked
Positions
5

Not financial advice. Hypothetical portfolio for informational purposes only. Returns are approximate and do not account for splits, dividends, borrow costs, or financing. Privacy notice.